Antibody responses to COVID-19 vaccination in cancer: a systematic review

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorŞahin, Taha Koray
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorUçkun, Fatih M.
dc.date.accessioned2021-11-26T10:42:48Z
dc.date.available2021-11-26T10:42:48Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: After the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for tumor type and active treatments. However, the data on the COVID-19 vaccine efficacy in cancer patients is limited due to exclusion of cancer patients from most vaccine clinical trials. Therefore, we systemically reviewed the available evidence evaluating the antibody responses in cancer patients. Methods: We conducted a systematic search from the Pubmed database and calculated risk differences (RD) and 95% confidence intervals (CI) to compare seroconversion rates between cancer patients and controls using the Review Manager software, version 5.3. Results: Our systematic search retrieved a total 27 studies and we included 17 studies with control arms in the analyses. Cancer patients had significantly lower seroconversion rates (37.3%) than controls (74.1%) (RD: -0.44, 95% CI: -0.52, -0.35, p<0.001) with first vaccine dose. After two doses, the seroconversion rates were 99.6% in control arm and 78.3% in cancer patients (RD: -0.19, 95% CI: -0.28, -0.10, p<0.001). The difference in seroconversion rates was more pronounced patients with hematologic malignancies (72.6%) (RD: -0.25, 95% CI: -0.27, -0.22, p<0.001) than patients with solid tumors (91.6%) (RD: -0.09, 95% CI: -0.13, -0.04, p<0.003) and patients in remission (RD: -0.10, 95% CI: -0.14, -0.06, p<0.001). Conclusion: In conclusion, COVID-19 vaccine seroconversion rates were significantly lower in patients with hematological malignancies and patients under active treatment. Further research focusing on the approaches to improve vaccine efficacy and exploration of novel treatment options is urgently needed for these patients.en_US
dc.identifier.citationGuven, D. C., Sahin, T. K., Kilickap, S., & Uckun, F. M. (2021). Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. Frontiers in oncology, 11, 759108.en_US
dc.identifier.doi10.3389/fonc.2021.759108en_US
dc.identifier.endpage14en_US
dc.identifier.pmid34804957en_US
dc.identifier.scopus2-s2.0-85119371174en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.3389/fonc.2021.759108
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2281
dc.identifier.volume11en_US
dc.identifier.wosWOS:000720450600001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherFrontiers Media SAen_US
dc.relation.ispartofFrontiers in Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectAntibodyen_US
dc.subjectCanceren_US
dc.subjectSeroconversionen_US
dc.subjectVaccinationen_US
dc.titleAntibody responses to COVID-19 vaccination in cancer: a systematic reviewen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
27.pdf
Boyut:
3.74 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu